EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Inhibition of head and neck squamous cell carcinoma by Bruton’s tyrosine kinase inhibitor ibrutinib is associated with reduction of immunosuppressive T cells

Anna R Bopp, Felipe F Lamenza, Puja Upadhaya, Nathan M Ryan, Natalie Kazmierowicz, Pete P Jordanides, Arham Siddiqui, Sherefuddin H Pracha, Peyton Roth, O Hans Iwenofu, Steve Oghumu

Cancer Immunology, Immunotherapy · 2025

DOI: 10.1007/s00262-025-04081-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Anna R Bopp und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center,…. Hauptthemen laut MEDLINE: Pyrimidines, Agammaglobulinaemia Tyrosine Kinase, Pyrazoles, Squamous Cell Carcinoma of Head and Neck. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDA NIH HHS, NIDCR NIH HHS, American Cancer Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Head and neck squamous cell carcinoma (HNSCC) is one of the most diagnosed malignancies globally, with a 5-year survival rate of only 40-50%. Current therapies are limited to aggressive chemoradiotherapy combinations and disfiguring resection. Recent research has demonstrated that inhibition of Bruton's tyrosine kinase (BTK) by ibrutinib is an effective treatment for aggressive solid cancers. However, little is known about the effects of ibrutinib on aggressive HNSCC. We tested the efficacy of ibrutinib against HNSCC in vitro and in a metastatic, aggressive MOC2 orthotopic murine model and determined the underlying mechanisms. Ibrutinib decreased cancer cell growth in vitro, reduced tumor burden in vivo, decreased metastasis to the tumor draining lymph nodes and lungs, and enhanced overall survival outcomes. Flow cytometric analysis revealed decreased infiltration of tumor-infiltrating immunosuppressive T cells expressing the co-inhibitory markers PD-1, LAG-3, and IL-10. Furthermore, ibrutinib treatment increased cytotoxic T cell infiltration into the tumor microenvironment. Further analysis demonstrated that the effects on immunosuppressive T cell phenotypes were directly mediated by ibrutinib. Immunosuppressive myeloid cells were also observed to express lower levels of PDL1 in ibrutinib-treated mice. Our study demonstrates the potential of BTK inhibitors, specifically ibrutinib, in the treatment of HNSCC, mediated by its inhibitory effect on HNSCC cancer cell growth and metastasis, as well as modulation of the T cell anti-tumor immune microenvironment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrimidinesAgammaglobulinaemia Tyrosine KinasePyrazolesSquamous Cell Carcinoma of Head and NeckHead and Neck NeoplasmsProtein Kinase InhibitorsT-LymphocytesCarcinoma, Squamous CellPiperidinesAnimalsAdenineMiceHumansTumor MicroenvironmentCell Line, TumorXenograft Model Antitumor AssaysLymphocytes, Tumor-InfiltratingTyrosine Kinase Inhibitors

Stichwörter der Autor:innen

HNSCCIbrutinibInterleukin 10T cells

Substanzen

ibrutinibPiperidinesAdeninePyrimidinesAgammaglobulinaemia Tyrosine KinasePyrazolesProtein Kinase InhibitorsTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Pathology, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, 249 Evans Hall, 520 King Ave., Columbus, OH, 43201, USA.
  • Department of Pathology, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, 249 Evans Hall, 520 King Ave., Columbus, OH, 43201, USA. oghumu.1@osu…

Förderung

  • NIDA NIH HHS
  • NIDCR NIH HHS
  • American Cancer Society
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Bopp, A. R., Lamenza, F. F., Upadhaya, P., Ryan, N. M., Kazmierowicz, N., Jordanides, P. P., Siddiqui, A., Pracha, S. H., Roth, P., Iwenofu, O. H., & Oghumu, S. (2025). Inhibition of head and neck squamous cell carcinoma by Bruton’s tyrosine kinase inhibitor ibrutinib is associated with reduction of immunosuppressive T cells. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-04081-5

Vancouver

Bopp AR, Lamenza FF, Upadhaya P, Ryan NM, Kazmierowicz N, Jordanides PP, et al. Inhibition of head and neck squamous cell carcinoma by Bruton’s tyrosine kinase inhibitor ibrutinib is associated with reduction of immunosuppressive T cells. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-025-04081-5

BibTeX
@article{Bopp2025,
  author = {Bopp, Anna R and Lamenza, Felipe F and Upadhaya, Puja and Ryan, Nathan M and Kazmierowicz, Natalie and Jordanides, Pete P and Siddiqui, Arham and Pracha, Sherefuddin H and Roth, Peyton and Iwenofu, O Hans and Oghumu, Steve},
  title = {Inhibition of head and neck squamous cell carcinoma by Bruton’s tyrosine kinase inhibitor ibrutinib is associated with reduction of immunosuppressive T cells},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2025},
  doi = {10.1007/s00262-025-04081-5}
}
Kostenlos starten →